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a  b  s  t  r  a  c  t
There  is  currently  an  ongoing  worldwide  pandemic  of a novel  virus  belonging  to  the  family  of Coro-
naviruses  (CoVs)  which  are  large,  enveloped,  plus-stranded  RNA viruses.  Coronaviruses  belong  to the
order of Nidovirales,  family  of  Coronavirinae  and  are  divided  into  four  genera:  alphacoronavirus,  beta-
coronavirus,  gammacoronavirus  and deltacoronavirus.  CoVs  cause  diseases  in a wide  variety  of  birds  and
mammals  and  have  been  found  in humans  since  1960.  To date,  seven  human  CoVs  were  identified  includ-
ing  the  alpha-CoVs  HCoVs-NL63  and  HCoVs-229E  and  the  beta-CoVs  HCoVs-OC43,  HCoVs-HKU1,  the
severe  acute  respiratory  syndrome-CoV  (SARS-CoV),  the  Middle  East  respiratory  syndrome-CoV  (MERS-
CoV)  and  the  novel  virus  that  first  appeared  in  December  2019  in Wuhan,  China,  and  rapidly  spread  to
213  countries  as  of  the  writing  this  paper.  It was  officially  named  severe  acute  respiratory  syndrome
coronavirus  2 (SARS-CoV-2)  by the international  committee  on  taxonomy  of  viruses  (ICTV)  and  the  dis-
ease’s name  is  COVID-19  for coronavirus  disease  2019.  SARS-CoV-2  is  very  contagious  and  is capable  of
spreading  from  human  to human.  Infection  routes  include  droplet  and  contact,  and  aerosol  transmission
is  currently  under  investigation.  It is associated  with  a respiratory  illness  that  may  cause  severe  pneumo-
nia  and  acute  respiratory  distress  syndrome  (ARDS).  SARS-CoV-2  became  an emergency  of international
concern.  As  of July 12, 2020,  the  virus  has been  responsible  for  12,698,995  confirmed  cases  and  564,924
deaths  worldwide  and  the  number  is  still increasing.  Up  until  now,  no  specific  treatment  has  yet  been
proven  effective  against  SARS-CoV-2.  Since  the  beginning  of  this  outbreak,  several  interesting  papers  on
SARS-CoV-2  and  COVID-19  have  been  published  to report  on  the  phylogenetic  evolution,  epidemiology,
pathogenesis,  transmission  as  well  as  clinical  characteristics  of  COVID-19  and  possible  treatments  agents.This  paper  is a  systematic  review  of  the  available  literature  on SARS-CoV-2.  It  was  performed  in accor-
dance  with  PRISMA  (Preferred  Reporting  Items  for Systematic  Reviews  and  Meta-Analyses)  and  aims
to help  readers  access  the  latest  knowledge  surrounding  this  new infectious  disease  and  to  provide  a
reference  for future  studies.
ï¾©  2020  The  Author(s).  Published  by  Elsevier  Ltd on  behalf  of King  Saud  Bin  Abdulaziz  University  for
Health  Sciences.  This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ntroduction
Coronaviruses (CoV) are the largest known RNA viruses. Their
ize varies from 65 to 125 nm in diameter and their nucleic acid
enome is single-stranded RNA, size ranging from 26 to 32 kb in
ength [1]. Since 1960, six coronaviruses have been found to cause
iseases in humans; SARS-CoV-2 is the seventh one, after SARS-CoV
nd MERS-CoV [2]. While HKU1, NL63, OC43 and 229E are associ-
ted with mild symptoms in humans, SARS-CoV, MERS-CoV, and
ARS-CoV-2, belonging to the betacoronavirus genus, cause severe
o deadly pneumonia in humans [3]. Fever, dry cough, difficulty
reathing and fatigue usually accompany this pneumonia [4,5]. The
atality rates of SARS-CoV, MERS-CoV and SARS-CoV-2 are 9.5%,
4.4%, and 2.3% respectively [6]. COVID-19 shows some particu-
ar pathogenic, epidemiological and clinical features which have
re not completely understood to date as well as its wide and high
ransmission in the community versus nosocomial spread of SARS
nd MERS and its milder infection and low mortality compared to
he severe phenotype and higher mortality caused by the two oth-
rs viruses [7]. To date, no therapeutic or vaccines were approved
gainst any of the known human coronaviruses and only protec-
ive measures were put in place. Based on the current published
iterature, we summarize in this paper the origin of this novel virus
nd its life cycle, the clinical characteristics of the disease, the possi-
le transmission routes, the pathogenesis, the prevention measures




The present study was conducted following the PRISMA
uidelines [8]. We  performed a systematic search for accessible
eer-reviewed and full articles published from December 2019 to
ay  2020. The literature search was updated in July 2020 while
eviewing the paper prior to its resubmission. Articles for review
ere selected from the following databases MEDLINE (PubMed),
eb  of Science and Google Scholar. The search terms included com-
inations of “COVID-19, SARS-CoV-2, new coronavirus, emergence,
ymptoms, multiplication cycle, transmission, diagnosis tests, pre-
ention, and treatment”. Full-text versions of the included papers
ere retrieved. The reference lists of relevant studies were also
ssessed. .  .  . . .  . . .  . .  . .  . .  .  . . . . . .  . . . . .  . . .  . . . . . . .  . . .  . . . . . . .  .  . . . .  .  .  .  . .  . . . .  .  . . . . .  .  . .  .  . .  . .1608
Inclusion and exclusion criteria
Inclusion and exclusion criteria were recorded following
PRISMA guidelines presented in the form of a PRISMA flow dia-
gram (Fig. 1). Briefly, the retrieved literature was imported into
Endnote software (v. × 9.0) and screened for exclusion criteria.
First, duplicate literature was  removed by Endnote, and then obvi-
ously inappropriate ones were eliminated based on the title and
abstract. Finally, remaining inappropriate entries were eliminated
by reading the full articles. The exclusion criteria for articles were
non-English studies, entries with only an abstract, those with no
relevant topic, and studies containing no useful or duplicated data
from previously published studies. The inclusion criteria are arti-
cles reporting confirmed SARS-CoV-2 positive patients, and studies
presenting original data as well as clear and precise end-point out-
comes.
Data extraction and synthesis
The authors independently extracted important information
from each article fulfilling the inclusion criteria and reviewed each
paper to verify the accuracy and coherence of collected data. Argu-
ments or disagreements were resolved following discussions. The
consensus extracted data were synthesized in the present paper.
Ethical approval was not required for this review of existing peer-
reviewed papers.
Results
We  identified 170 papers through PubMed, Web  of science
and Google Scholar databases and 20 papers through reference
cross-check and internet research of conference abstracts. After
duplicate removal, a total of 130 papers were screened for rele-
vance. Abstracts and titles screening identified 32 studies that met
the inclusion criteria. After the full-text analyses, 12 of these stud-
ies were excluded. Hence, twenty studies were eligible according
to our criteria and were included in this review (Fig. 1).
SARS-CoV-2 emergence
Coronaviruses have been described as causing several systemic
infections in their selected animal host [9]. However, some of
them can adapt dramatically and jump the species barrier by nat-
ural recombination causing epidemics or pandemics. Infection in
human often leads to severe clinical symptoms and high mortal-
ity (https://www.who.int/emergencies/mers-cov/en/). We  present
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Fig. 1. PRISMA flowchart of literature search strategy.
Fig. 2. Emergence of human coronaviruses: As of July 12, 2020, seven CoVs are known to be human pathogens including the alpha-CoVs HCoVs-NL63 (1200-1500) and
HCoVs-229E (1700-1800) and the beta-CoVs HCoVs-OC43 (1890), HCoVs-HKU1 (1950), severe acute respiratory syndrome-CoV (SARS-CoV) (2002), Middle East respiratory
syndrome-CoV (MERS-CoV) (2012) and the novel SARS-CoV-2 (2019).
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Fig. 3. SARS-CoV-2 situation update worldwide: As of July 12, 2020, 12,698,995 cases of COVID-19 have been reported in the world including 564,924 deaths. The most
affected continent is the America with 6,685,097 confirmed cases and 286,796 deaths on this day (https://www.ecdc.europa.eu/).
Table 1
Comparative analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2.
Coronavirus SARS-CoV MERS-CoV SARS-CoV-2
Emergency year 2002 2013 2019
Emergency area Guangdong province, China Arabian peninsula Wuhan, China
Number of infected countries 29 27 213
Animal reservoir Bat Bat Bat
Intermediate host Palm civets Camels Unknown
incubation time in humans (days) 2–7 2–14 2–14
Caused disease Severe acute respiratory syndrome
(SARS)




Clinical symptoms Malaise, diarrhea, cough, fever and
shortness of breath
Pneumonia, acute respiratory
distress syndrome, renal failure
Cough, fever and shortness of
breath
Number of infected patients 8098 2494 3,646,304















Entry receptor in human cells Angiotensin-converting enzyme 2
(ACE2)
Used  therapy Supportive care 
n Fig. 2 the appearance of the seven human coronaviruses over
he time (Fig. 2). In 2002, in Guangdong (China), the SARS-CoV
irus emerged and spread to the five continents infecting 8098
eople and causing 774 deaths (9.5% of cases). In 2012, MERS-
oV emerged in the Arabian Peninsula infecting 2494 people in
7 countries and causing 858 deaths (34.4% of cases) [10]. In late
ecember 2019, SARS-CoV-2 emerged in a seafood market (where
everal wildlife species are sold including bats, rabbits, snakes, birds
nd frogs) in Wuhan City, Hubei province, China [11]. As of July
2, 2020, this virus has been responsible for 12,698,995 confirmed
ases and 564,924 deaths worldwide (2.3%). SARS-CoV-2 spread
apidly to 213 countries (at the time of revision), and the most
ffected continents are the America and Europe with 6,685,097
nd 2,572,406 confirmed cases respectively since 31 DecemberDipeptidyl peptidase 4 (DPP4) Angiotensin-converting enzyme 2
(ACE2)
Supportive care Supportive care
2019 and as of July 12, 2020. In America, 286,796 persons were
died and 196,096 ones in Europe until this day (https://www.ecdc.
europa.eu/) (Fig. 3). On January 30, 2020, the World Health Orga-
nization (WHO) declared the SARS-CoV-2 epidemic as a public
health emergency of international concern [12]. On March 11, 2020,
the WHO  issued an announcement of the change in COVID-19’s
status from an epidemic to pandemic disease. It was  suggested
that MERS-CoV, SARS-CoV and SARS-CoV-2 originated from bats
[13]. Phylogenetic analyses showed that SARS-CoV-2, SARS-CoV
and SARS-like coronaviruses isolated in bats belong to a different
clade than MERS-CoV, with a complete genome nucleotide iden-
tity between SARS-CoV-2 and SARS-CoV of 79.5% and between
SARS-CoV-2 and bat SARS coronavirus (SARSr-CoV-RaTG13) of 96%

































































M. Bchetnia et al. / Journal of Infectio
eservoir host fuelling spillover to humans for SARS-CoV [15,16],
hile MERS-CoV’s intermediate host is unequivocally dromedary
amels [17,18]. For SARS-CoV-2, pangolins and snakes are thought
o be potential intermediate hosts but this requires further con-
rmation [19]. More evidence is needed to confirm the origin of
his novel virus and its transmission to humans, to understand the
est way to prevent and slow down its transmission and to bet-
er control of future zoonotic events. In Table 1, we summarize the
rincipal characteristics of SARS-CoV, MERS-CoV and SARS-CoV-2.
riefly, bats seem to be the common natural origin of SARS-CoV-2,
ARS-CoV and MERS-CoV. The clinical features of the three viruses
re quite similar. However, unlike SARS-CoV and MERS-CoV, SARS-
oV-2 is more contagious and spreads rapidly, currently affecting
ore than 213 countries (https://www.who.int). SARS-CoV-2 uses
he SARS-CoV receptor angiotensin-converting enzyme 2 (ACE2)
n host target cells; however, MERS-CoV binds to the dipeptidyl
eptidase 4 receptor (DDP4) [20]. According to the latest studies,
ARS-CoV-2 has the highest number of casualties but its mortal-
ty rate is lower (2.3%) compared to SARS-CoV (9.5%) and MERS
34.4%) [6]. Therefore, SARS-CoV-2 resembles both SARS-CoV and
ERS-CoV, but appears unique in its high transmission rates.
linical features and pathogenesis
COVID-19 is a highly contagious disease. Its clinical manifesta-
ions range from mild to severe but most infected cases present
 mild form of the disease and therefore have no severe clinical
eatures [21]. Based on current data, 81% of the cases exhibit mild
ymptoms and 1.2% are asymptomatic (http://weekly.chinacdc.cn).
ARS-CoV-2 can spread rapidly in the community contrarily to
ARS CoV and MERS-CoV that have a higher mortality rate but a
tronger nosocomial than community transmissibility. This is likely
ue to the fact that they cause a more severe clinical phenotype
han COVID-19 [6]. It was reported that COVID-19 average incuba-
ion period is 5.2 days (95% confidence interval (CI), 4.1–7.0) with
he 95th percentile at 12.5 days [22]. Another study estimated it
t 6.4 days (95% CI, 5.6–7.7) [23]. The median age of COVID-19
ases ranges from 49 to 57 years [6] and median time from the
rst symptom to death is 14 days [24]. While a detailed clinical
andscape continues to be established, the most common clinical
ymptoms of SARS-CoV-2 observed in patients were fever (87.9%),
ough (67.7%) and fatigue (38.1%), whereas diarrhea (3.7%) and
omiting (5.0%) were occasional [24,25]. All patients had pneu-
onia and about half had dyspnea [26]. Some COVID-19 patients
howed arrhythmia, acute heart injury, impaired renal function
nd abnormal liver function (50.7%) at admission [27,28]. In addi-
ion, there is evidence of ocular surface infection in patients with
OVID-19 as SARS-CoV-2 RNA was detected in eye secretions of
atients [29,30]. A retrospective case series study conducted on
14 infected patients from Wuhan showed that 78 (36.4%) patients
isplayed neurologic manifestations [31]. Furthermore, diminished
bility to smell or taste observed in some patients [32,33] was
ound to result from a neurotropic or neurovirulent viral infection
f the olfactory system [34]. The older population and individuals
ith underlying health complications as cardiovascular diseases
nd diabetes were reported to present the severe disease symptoms
35]. Children were found less vulnerable than the elder population
36,37]. Pregnant women may  be more vulnerable to SARS-CoV-2
s this virus may  alter the immune responses at the maternal-
etal interface, and affect the well-being of mothers and infants
38]. A retrospective study based on nine pregnant women infected
y COVID-19 showed no evidence of intrauterine vertical trans-
ission between mothers and infants in the late pregnancy [39].
o avoid SARS-CoV-2 newborns infections after birth, immediate
revention instructions should be implemented for these women
nd their neonates, including a 14-day isolation for newborns Public Health 13 (2020) 1601–1610 1605
and avoiding breast feeding during this period [40]. Laboratory
findings showed typical CT results including bilateral pulmonary
parenchymal ground glass and consolidated pulmonary opacities
sometimes with a rounded morphology and peripheral lung distri-
bution [41]. Ground-glass-like lung images are probably due to the
severe inflammation of lung cells becoming unable to exchange car-
bon dioxide and oxygen after SARS-CoV-2 infection [42]. A recent
study showed that that SARS-CoV-2 could infect T cells explaining
the lymphocytopenia commonly found in COVID-19 patients [43].
It was also observed that most critically ill patients infected with
SARS-CoV-2 had elevated levels of inflammatory cytokines (IL-6
and IL-10) [44], indicating potential bacterial co-infection caused
by dysregulated immune system [45]. Moreover, Nguyen team,
by using in silico analysis, showed that genetic variability across
the three major histocompatibility complex (MHC) class I genes
(human leukocyte antigen [HLA] A, B, and C) may affect suscepti-
bility to and severity of COVID-19 which need further experimental
investigation [46].
SARS-CoV-2 transmission
Understanding transmission pathways of SARS-CoV-2 has sig-
nificant implications for intervention and prevention. It was
initially suggested that Chinese patients infected with SARS-CoV-
2 may  have visited the seafood market in Wuhan City or may
have consumed infected animals. However, further investigation
revealed that some individuals contracted the COVID-19 with-
out visiting the market. Indeed, an epidemiological study in early
cases in this city showed that only 22% of patients were directly
exposed to the marketplace, 32% of cases were in close contact
with the suspected cases and 51% had no contact with either source
[47]. This suggests a human-to-human transmission of the virus
and an ability to propagate, resulting in disease clusters from a
single index patient [48,49]. The WHO  estimated the reproduc-
tive number (R0) of SARS-CoV-2 to range between 2 and 2.5,
which is higher than SARS (1.7–1.9) and MERS (<1). This sug-
gests that SARS-CoV-2 has a higher pandemic potential [50,51].
Three transmission ways of SARS-CoV-2 in humans were pro-
posed with incubation times of 2–14 days: 1) contact with liquid
droplets produced by infected patients and/or 2) close contact with
infected individuals and 3) contact with surfaces and material con-
taminated with SARS-CoV-2 (https://www.cdc.gov/coronavirus/
2019ncov/about/transmission). In experimental setups, infectious
viruses could be detected up to 24 h on cardboard, up to 2–3 days
on plastic and stainless steel and up to 3 h post aerosolization
(van Doremalen et al. 2020). Certain scientists recently highlighted
another possible transmission route, the airborne transmission
through droplet nuclei (or aerosols), meaning the possibility of
the disease spreading in much smaller particles from exhaled air,
known as aerosols. They are suggesting that aerosols are also more
likely than droplets to be produced by talking and breathing and
might pose a higher probability of transmission than coughing and
sneezing [52]. In lab experiments, infectious SARS-CoV-2 particles
were detected in aerosols for 3 h [53]. Liu and colleagues at Wuhan
University collected samples of aerosols in and around hospitals
treating COVID-19 patients and found viral RNA from SARS-CoV-
2 on protective apparel and floor surface and their subsequent
resuspension. In this study, viral RNA concentration in aerosol sam-
ples was low (0–42 genomes/cubic metre of air) [54]. An American
team studied the presence of SARS-CoV-2 in air samples and sur-
faces from 11 isolation rooms of COVID-19 patients and showed
that many (63%) of air samples had evidence of viral contamina-
tion, with higher airborne virus concentration (2860 copies per
cubic metre of air) [55]. It is noteworthy to mention that infectious
viruses have not been recovered from aerosols in any study. In a
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onfirmed COVID-19 cases in the largest clinical hospital in Iran
howed that all air samples were negative [56]. This may  be because
f air sampling processes damaging the viruses or because the virus
oes not resist easily to aerosolization process. Finally, given the
eneral scientific knowledge about aerosol long distance indoor
ransport, aerosol scientists have proposed that airborne trans-
ission of SARS-CoV-2 is most likely to occur in poorly ventilated
paces [57].
ARS-CoV-2 structure and cells infection
SARS-CoV-2 RNA genome is 29.9 kb [58]. It contains 14 open
eading frames (ORFs), encoding 27 proteins. At the 5’-terminal
egion of the genome, the ORF1 and ORF2 encode 15 non-structural
roteins important for virus multiplication. The 3’-terminal region
f the genome encodes functional structural proteins, namely spike
S), envelope protein (E), membrane protein (M)  and nucleocapsid
N), plus 8 accessory proteins [58,59]. Phylogenetic and compu-
ational genomic analyses suggest that to enter in host’s cells,
ARS-CoV-2 shares the same human cell receptor with SARS-CoV
ACE2), while MERS-CoV uses another (DPP4) [20]. ACE2 is an
ctoenzyme anchored to the plasma membrane of the cells of
everal tissues, particularly in the lower respiratory tract, heart,
idneys and gastrointestinal tract [60]. A structure model anal-
sis shows that SARS-CoV-2 binds ACE2 with above 10 folds
reater affinity than SARS-CoV, and much higher than the threshold
equired for viral infection [61]. The Spike (S) protein (of about 150
Da) is the major antigen presented on the surface of SARS-CoV-2.
he S protein forms a transmembrane homotrimer protruding from
he viral surface to attach to the host cellular receptor ACE2. S com-
rises two functional subunits: subunit S1 responsible for binding
o the cell surface receptor ACE2 and subunit S2 responsible viral
usion to the cell membrane [62].
SARS-CoV-2 hijacks host cells (such as lung cells) by endocytosis
63,64]. First, S protein binds to the cellular receptor ACE2 [65]. This
ttachment is followed by activation of the S protein, which initi-
tes fusion of the viral membrane with the membrane of the host
ell [10]. This fusion allows the virus to enter the cells [66]. SARS-
oV-2 releases its genetic material into the cell cytoplasm where
t is translated into the viral replicase polyproteins pp1a and 1ab.
p1a and p1ab are then cleaved by viral proteinases to form func-
ional non-structural proteins (NSPs) such as a helicase (Hel) and
he RNA-dependent RNA polymerase (RdRp) which is responsible
or replication of structural protein RNA [67]. The plus-stranded
NA genome of SARS-CoV-2 will serve to synthetize subgenomic
egative-strand templates that serve as templates for mRNA syn-
hesis. Structural proteins S1, S2, E, and M are then translated by
ibosomes that are bound to the endoplasmic reticulum (ER) [68].
iral nucleocapsids (N) are assembled from genomic RNA, followed
y budding into the lumen of the endoplasmic reticulum (ER)–Golgi
ntermediate compartment (ERGIC) [69]. The nucleocapsids fuse
ith the virion precursor. Formed virions will then be transported
rom the ER through the Golgi apparatus to the cell surface via small
esicles and released from the cell through exocytosis [70] (Fig. 4).
ARS-CoV-2 diagnosis tests
Diagnostic tests were developed rapidly after the start of the
ARS-CoV-2 outbreak allowing early recognition and detection
f this novel virus. Nasopharyngeal swabs are the recom-
ended specimen for molecular analysis. As of 19 March
020, the CDC made oropharyngeal, mid-turbinate, and nasal
wabs acceptable specimen types if nasopharyngeal swabs are
ot available (https://www.cdc.gov/coronavirus/2019-nCoV/lab/
uidelines-clinical-specimens.html). Samples are collected from
he upper respiratory tract (oropharyngeal and nasopharyngeal) Public Health 13 (2020) 1601–1610
and lower respiratory tract (endotracheal aspirate, expectorated
sputum, or bronchoalveolar lavage) of patients suspected SARS-
CoV-2 infection [71].
At the initial stage of the outbreak, identification of COVID-
19 cases mainly involved virus isolation from swabs and viral
nucleic acid detection by RT-PCR-based SARS-CoV-2 RNA detec-
tion in respiratory samples. Enzyme-linked immunosorbent assay
(ELISA) kits for detection of IgM and IgG antibodies against N
and other SARS-CoV-2 proteins have also recently been made
available. Several other diagnostic tests are developed to detect
other regions of the SARS-CoV-2 genome or targeting RdRp, Hel,
S, E and N genes [72]. Another easy-to-implement and accurate
CRISPR–Cas12-based lateral flow assay for detection of SARS-CoV-2
from respiratory swab RNA extracts in just 30 min  is under develop-
ment [73]. Currently there are 628 SARS-CoV-2 tests commercially
available or in development for the diagnosis of COVID-19 https://
www.finddx.org/covid-19/pipeline/.
SARS-CoV-2 treatment
To date, no vaccines or therapies have been approved to treat
any of the known human coronaviruses. The rapid global spread of
COVID-19 has emphasized the need for the development of new
coronavirus vaccines and therapeutics for this family of viruses.
Treatment will reduce the economic impact on the world as SARS-
CoV had a history of taxing the global economy 30 US $ to 100 US
$ billion [74]. Since the beginning of the COVID-19 outbreak, the
WHO has encouraged researchers all over the world to develop a
cure for this disease. Here we present some of these initiatives that
are still in early stages of development.
Antiviral agents
Randomized controlled trials were initiated and are being con-
ducted for many antiviral agents. Lopinavir (LPV) was  shown to
inhibit the protease activity of coronavirus in vitro and in animal
models and already used for SARS and MERS in combination with
ritonavir, another antiviral drug [75,76]. However, a recent trial
showed lopinavir-ritonavir has no treatment benefit for severely
infected patients by SARS-CoV-2 [77]. Ribavirin is a guanosine ana-
logue, used to treat several viral infections including those caused
by the hepatitis C and respiratory syncytial viruses by targetting the
RdRp complex [78]. Messenger RNA (mRNA) vaccine technology is
also under development (in phase 1 clinical trial by the US National
Institute of Allergy and Infectious Diseases) [79].
Remdesivir, a nucleotide analog antiviral inhibitor that may
compete for RdRp, was  designed for the Ebola virus and was with
efficient against MERS and SARS [80]. Remdesivir has been reported
to inhibit in vitro SARS-CoV-2 proliferation and therefore has clin-
ical therapeutic potential [81]. Recently, Remdesivir was used in a
clinical trial including 53 COVID-19 patients. Results showed clini-
cal improvement in 36 of the 53 patients (68%). However, this drug
needs to be used especially for patients not receiving invasive ven-
tilation as the mortality rate was  18% when receiving ventilation,
compared to 5% when not receiving [82].
Chloroquine and hydroxychloroquine
Chloroquine is antimalarial and autoimmune disease drug. It
blocks viral infection by increasing endosomal pH limiting virus to
cell fusion as well as interfering with the glycosylation of cellular
receptor ACE2 [83]. Hydroxychloroquine is an analog of chloro-
quine. Both drugs have immunomodulatory effect and can supress
the immune response of IL-6 and IL-10 that have been reported
to be increased in response to SARS-CoV-2 [84]. Clinical controlled
trials have shown that chloroquine was proved to be effective in
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Fig. 4. SARS-CoV-2 life cycle in infected cells and inhibition targets: SARS-CoV-2 begins its life cycle by binding of the S protein presented on the surface of the virus to
the  cellular receptor ACE2 on the target cell. After receptor binding, the S protein changes conformation, facilitating viral envelope fusion with the infected cell membrane
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hrough endocytosis. SARS-CoV-2 then releases its genetic material into the host c
hen  cleaved into small products by viral proteinases. By discontinuous transcriptio
roteins. The positive-sense genomic RNA is then packaged into a ribonucleocapsid
aturation. Virions are finally transported via small vesicles and released out of the
he treatment of COVID-19 by reducing pneumonia exacerbation
nd was included in the recommendations for the prevention and
reatments of SARS-CoV-2 [85].
orticosteroids
Corticosteroids could supress lung inflammation but their use
or the treatment of COVID-19 lung injury is not supported by
linical evidence as the clearance of viral infection is delayed
nd also due to the occurrence of side complications [86,87]. The
HO advises against the use of corticosteroids unless indicated for
nother reason [72].
ntibodies
The spike protein S is the principal target of antibodies. The
ARS-CoV monoclonal antibody CR3022, a neutralizing antibody
reviously isolated from a convalescent SARS patient, was identi-
ed to bind potently with this protein [88]. This antibody may  be a
otential therapeutic candidate.onvalescent plasma transfusion (CP)
Convalescent plasma transfusion (CP) therapy was successfully
sed in the treatment of SARS, MERS and during the 2009 H1N1nomic RNA is translated into viral replicase polyproteins pp1a and 1ab, which are
 polymerase produces a series of subgenomic mRNAs that are translated into viral
s assembled into viral particles in the ER and Golgi apparatus where they undergo
hrough exocytosis. Inhibition targets are presented in red.
pandemic with acceptable efficacy and safety [89–91]. It consists of
collecting convalescent plasma from patients 2 weeks after recov-
ery, to ensure neutralisation and a high antibodies titer followed
by its administration to infected patients. Duan and his colleagues
(2020) performed a pilot study in three participating hospitals
in China to explore the feasibility of CP treatment in 10 severe
COVID-19 patients. They showed that clinical symptoms signifi-
cantly improved with the increase of oxyhemoglobin saturation
within 3 days, accompanied by rapid neutralization of viremia
[92]. Another study performed on an uncontrolled case series of
five critically infected patients, showed improvement in their clin-
ical symptoms [93]. Despite CP being an effective way to improve
survival rate of severely infected patients, it does not permit the
patient to acquire a SARS-CoV-2 immune protection and the safety
of plasma globulin products specific to SARS-CoV-2 deserves fur-
ther consideration [94].
Global SARS-CoV-2 prevention measuresGiven the lack of available effective vaccine or treatments,
it is primordial to control the source of infection and cut off
the transmission route of SARS-CoV-2 by implementing robust
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acts and fomites are the most common ways of transmission for
ARS-CoV-2. Aerosol transmission is still controversial. The WHO
ecommended several standard procedures for slowing the spread
f COVID-19 by raising awareness on the prevention and control of
he disease in the general population. The bulk of these strategies
nvolve restricting mass gathering by advising the population to be
onfined and avoid close contact with anyone showing symptoms
f respiratory illness in order to decrease the risk of spreading by
reaking the transmission chain. Thus, many countries suspended
ll types (cultural, social, religious, scientific, sporting, and political)
f mass gatherings and opted for videoconferences, and telecom-
uting. The WHO  also recommended to maintain personal hygiene
specially regular hand washing with soap and water or hand
anitizer containing at least 60% alcohol, a healthy lifestyle and
dequate nutritional intake [95]. Outside, people need to respect
inimum 2 m social distancing and it is preferred to wear protec-
ive masks. To limit aerosol transmission, it is important to keep
egular room ventilation and effective sanitization [24].
In the face of this pandemic, some countries showed good
OVID-19 curve control because they rapidly deployed intense case
nding measures to stop virus transmission. For example, South
orea dramatically slowed the epidemic by performing more than
00 000 diagnostic tests (5,828.6 tests per million) in the 9 weeks
fter the first case was described. Individuals who tested posi-
ive were identified and isolated [96]. Singapore used a broad case
efinition, aggressive contact tracing, and isolation by testing all
atients with pneumonia and influenza-like illnesses in primary
are settings and hospitals, severely sick patients in intensive care,
nd deaths with a possible infectious disease [97]. Taiwan and Hong
ong used similar strategies [98].
onclusion
The international alert about the COVID-19 infection has helped
n the containment of SARS-CoV-2. At the date of writing, COVID-
9 showed promising signs of ending. Many countries seem to be
fficiently controlling this SARS-CoV-2 pandemic wave and have
onsiderably limited the mortality rate thanks to knowledge gar-
ered in the past from SARS and MERS epidemics, allowing for the
apid institution of more efficient preventive measures. However,
ARS-CoV-2 is far from being eradicated and many researchers pre-
ict novel waves in the future. That is why research efforts on
ARS-CoV-2 and COVID-19 need to be redoubled to discover effi-
ient treatments as soon as possible. Several promising competitive
herapeutic options are currently under development all over the
orld but require time to for validation and commercialization.
here is still much to learn about COVID-19 and it critical that sci-
ntist around the world collaborate and share information in order
o face this new global threat and to develop a suitable cure to
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